ArticleTurkish journal of urology2017
Predictive value of preoperative neutrophil-to-lymphocyte ratio on the prognosis of germ cell testicular tumors.
Article in Turkish journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic and prognostic role of NLR in testicular cancer.Exploration of targeted anti-tumor therapy · 2024Pooled it
- The post-orchiectomy systemic inflammatory index is associated with tumor characteristics in clinical stage I germ cell tumors.Frontiers in oncology · 2025Article
- Prognostic Significance of Systemic Inflammation Markers in Testicular and Penile Cancer: A Narrative Review of Current Literature.Life (Basel, Switzerland) · 2023Review
- The changing landscape of immune cells in the fetal mouse testis.Histochemistry and cell biology · 2022Article
- Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular Cancer.Frontiers in oncology · 2022Review
- The values of systemic immune-inflammation index and neutrophil-lymphocyte ratio in predicting testicular germ cell tumors: A retrospective clinical study.Frontiers in oncology · 2022Article
- Review
- The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer.Current oncology (Toronto, Ont.) · 2020Article
- Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy.Frontiers in oncology · 2020Article
- Neutrophil-to-lymphocyte ratio independently predicts advanced pathological staging and poorer survival outcomes in testicular cancer.Investigative and clinical urology · 2019Article
- Systemic immune-inflammation index in germ-cell tumours.British journal of cancer · 2018Article
- Predictive and prognostic impact of preoperative complete blood count based systemic inflammatory markers in testicular cancer.International braz j urol : official journal of the Brazilian Society of UrologyArticle
- The relationship of neutrophil to lymphocyte ratio with testicular cancer.International braz j urol : official journal of the Brazilian Society of UrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe investigated the prognostic value of preoperative neutrophil-to-lymphocyte ratio (NLR) on germ cell testicular tumors (GCT). MATERIAL AND
methodsThe data of 53 patients who underwent inguinal orchiectomy were analyzed retrospectively. NLR was calculated from the preoperative complete blood cell counts. Receiver operating characteristic (ROC) analysis was performed to find the threshold values for NLR. Correlations between cancer-specific survival (CSS) and progression-free survival (PFS) and NLR were evaluated.
resultsThe mean follow-up time was 23.55±18.06 months. The mean level of NLR was 3.08±1.81. Optimal threshold values of NLR was calculated as 3.55 for PFS (area under curve, AUC: 0.55) and 3.0 for CSS (AUC: 0.66). For patients with a NLR of <3.55 and NLR of ≥3.55, mean times-to-progression were 55.71 months (95% CI, 51.27-60.14) and 51.95 months (95% CI, 38.02-65.87, p=0.152), respectively. As well as, for patients with a NLR of <3.0 and NLR of ≥3.0, mean times-to-cancer specific death were 54.72 months (95% CI, 49.05-60.38) and 49.43 months (95% CI, 37.64-61.22, p=0.119), respectively.
conclusionPreoperative NLR is not a useful tool to predict the prognosis of patients with GCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.